Login / Signup

Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer.

Yinu WangXiaolei SituHoracio CardenasEllie SiuSayedabdulrazzaq A AlhunayanRussell KeathleyEdward J TannerJian-Jun WeiYuying TanChinmayee Vallabh Prabhu DessaiJi-Xin ChengDaniela E Matei
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
NTX-301 is active in ovarian cancer models. Our findings point to a new mechanism by which epigenetic blockade disrupts lipid homeostasis and promotes cancer cell death.
Keyphrases